Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the clinical pipeline.
Kardigan plans to use the funds raised in this IPO to progress its pipeline of mid-to-late-stage cardiology candidates. Credit: Alex Syu / Shutterstock.com.
Just under a year and a half after its debut, Kardigan is eyeing a listing on the Nasdaq to support the continued development of its in-licensed cardiology pipeline – adding another name to the burgeoning list of American biotechs undertaking IPOs this year.
The ARCH Venture Partners-backed company will trade under the ticker “KARD.” While Kardigan has not yet revealed the number or price of shares it will offer, it did describe where the funds will be used. Primarily, proceeds will help progress three of the biotech’s pipeline cardiovascular therapies through the clinic. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
